Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase II Study of Bevacizumab to Prevent Radiation-Induced Brain Injury After SRT for Lung Cancer Brain Metastases
ChiCTR2500114822Phase 2Recruiting
- Sponsor
- Shandong First Medical University
- Start
- Dec 2025
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 2 trial of bevacizumab in bronchial carcinoma, brain metastases, radiation-induced encephalopathy (RIE) and 1 more (2 arms), sponsored by Shandong First Medical University. Primary endpoint: Incidence of grade ≥3 cerebral edema at 3 months after radiotherapy. Started Dec 2025; status: recruiting.
02
Drugs
bevacizumab
03
Conditions
bronchial carcinomabrain metastasesradiation-induced encephalopathy (RIE)cerebral edema
Beyond the preview
Go deeper on ChiCTR2500114822.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR2500114822.